Cargando…
Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting
BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) used for osteoarthritis (OA) in primary care may cause gastrointestinal or renal injury. This study estimated adherence to two quality indicators (QIs) to optimize NSAID safety: add proton pump inhibitors (PPI) to NSAIDs for patients with gas...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523610/ https://www.ncbi.nlm.nih.gov/pubmed/37759196 http://dx.doi.org/10.1186/s12891-023-06904-x |
_version_ | 1785110597057118208 |
---|---|
author | Swan, Joshua T. Rizk, Elsie Duong, Phuong Y Alghamdi, Bader M. Kaur, Navjot Nagaraj, Sudha Brown, Anthony E. Flores, Eleazar Spence, Nathan Tajchman, Sharla |
author_facet | Swan, Joshua T. Rizk, Elsie Duong, Phuong Y Alghamdi, Bader M. Kaur, Navjot Nagaraj, Sudha Brown, Anthony E. Flores, Eleazar Spence, Nathan Tajchman, Sharla |
author_sort | Swan, Joshua T. |
collection | PubMed |
description | BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) used for osteoarthritis (OA) in primary care may cause gastrointestinal or renal injury. This study estimated adherence to two quality indicators (QIs) to optimize NSAID safety: add proton pump inhibitors (PPI) to NSAIDs for patients with gastrointestinal (GI) risk (QI #1 NSAID-PPI) and avoid oral NSAIDs in chronic kidney disease (CKD) stage G4 or G5 (QI #2 NSAID-CKD). METHODS: This retrospective study included index primary care clinic visits for knee OA at our health system in 2019. The validation cohort consisted of a random sample of 60 patients. The remainder were included in the expanded cohort. Analysis of structured data extracts was validated against chart review of clinic visit notes (validation cohort) and estimated QI adherence (expanded cohort). RESULTS: Among 60 patients in the validation cohort, analysis of data extracts was validated against chart review for QI #1 NSAID-PPI (100% sensitivity and 91% specificity) and QI #2 NSAID-CKD (100% accuracy). Among 335 patients in the expanded cohort, 44% used NSAIDs, 27% used PPIs, 73% had elevated GI risk, and only 2% had CKD stage 4 or 5. Twenty-one percent used NSAIDs and had elevated GI risk but were not using PPIs. Therefore, adherence to QI #1 NSAID-PPI was 79% (95% CI, 74–83%). No patients with CKD stage 4 or 5 used NSAIDs. Therefore, adherence to QI #2 NSAID-CKD was 100%. CONCLUSION: A substantial proportion of knee OA patients with GI risk factors did not receive PPI with NSAID therapy during primary care visits. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-023-06904-x. |
format | Online Article Text |
id | pubmed-10523610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105236102023-09-28 Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting Swan, Joshua T. Rizk, Elsie Duong, Phuong Y Alghamdi, Bader M. Kaur, Navjot Nagaraj, Sudha Brown, Anthony E. Flores, Eleazar Spence, Nathan Tajchman, Sharla BMC Musculoskelet Disord Research BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) used for osteoarthritis (OA) in primary care may cause gastrointestinal or renal injury. This study estimated adherence to two quality indicators (QIs) to optimize NSAID safety: add proton pump inhibitors (PPI) to NSAIDs for patients with gastrointestinal (GI) risk (QI #1 NSAID-PPI) and avoid oral NSAIDs in chronic kidney disease (CKD) stage G4 or G5 (QI #2 NSAID-CKD). METHODS: This retrospective study included index primary care clinic visits for knee OA at our health system in 2019. The validation cohort consisted of a random sample of 60 patients. The remainder were included in the expanded cohort. Analysis of structured data extracts was validated against chart review of clinic visit notes (validation cohort) and estimated QI adherence (expanded cohort). RESULTS: Among 60 patients in the validation cohort, analysis of data extracts was validated against chart review for QI #1 NSAID-PPI (100% sensitivity and 91% specificity) and QI #2 NSAID-CKD (100% accuracy). Among 335 patients in the expanded cohort, 44% used NSAIDs, 27% used PPIs, 73% had elevated GI risk, and only 2% had CKD stage 4 or 5. Twenty-one percent used NSAIDs and had elevated GI risk but were not using PPIs. Therefore, adherence to QI #1 NSAID-PPI was 79% (95% CI, 74–83%). No patients with CKD stage 4 or 5 used NSAIDs. Therefore, adherence to QI #2 NSAID-CKD was 100%. CONCLUSION: A substantial proportion of knee OA patients with GI risk factors did not receive PPI with NSAID therapy during primary care visits. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-023-06904-x. BioMed Central 2023-09-27 /pmc/articles/PMC10523610/ /pubmed/37759196 http://dx.doi.org/10.1186/s12891-023-06904-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Swan, Joshua T. Rizk, Elsie Duong, Phuong Y Alghamdi, Bader M. Kaur, Navjot Nagaraj, Sudha Brown, Anthony E. Flores, Eleazar Spence, Nathan Tajchman, Sharla Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting |
title | Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting |
title_full | Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting |
title_fullStr | Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting |
title_full_unstemmed | Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting |
title_short | Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting |
title_sort | specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523610/ https://www.ncbi.nlm.nih.gov/pubmed/37759196 http://dx.doi.org/10.1186/s12891-023-06904-x |
work_keys_str_mv | AT swanjoshuat specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting AT rizkelsie specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting AT duongphuongy specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting AT alghamdibaderm specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting AT kaurnavjot specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting AT nagarajsudha specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting AT brownanthonye specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting AT floreseleazar specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting AT spencenathan specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting AT tajchmansharla specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting |